Cargando…

2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial

BACKGROUND: Patients hospitalized with sepsis are commonly treated with antibiotics for 10–21 days. Evidence is lacking to support this duration. We hypothesize that the sequential measurement of procalcitonin [PCT] (host biomarker) and endotoxin activity assay [EAA] (microorganism biomarker) could...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalil, Andre C, Florescu, Diana F, Shafer, Laura R, Van Schooneveld, Trevor C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810774/
http://dx.doi.org/10.1093/ofid/ofz360.1918
_version_ 1783462325262483456
author Kalil, Andre C
Florescu, Diana F
Shafer, Laura R
Van Schooneveld, Trevor C
author_facet Kalil, Andre C
Florescu, Diana F
Shafer, Laura R
Van Schooneveld, Trevor C
author_sort Kalil, Andre C
collection PubMed
description BACKGROUND: Patients hospitalized with sepsis are commonly treated with antibiotics for 10–21 days. Evidence is lacking to support this duration. We hypothesize that the sequential measurement of procalcitonin [PCT] (host biomarker) and endotoxin activity assay [EAA] (microorganism biomarker) could provide evidence to safely reduce antibiotic exposure. METHODS: Consented patients with bacteremic sepsis on antibiotics for <48 hours had PCT and EAA measured every other day until discharge or 14 days. Investigators and care providers were blinded to results. Median (interquartile), days to biomarker clearance (reduction from baseline PCT> 80% and EAA> 0.1), and univariate/multivariate regression done for all analyses. Clinical response was evaluated by blinded investigators. RESULTS: We enrolled 215 patients. Median age: 60 years old (18); Female 45%; Baseline: Temperature: 38.5°C (0.7); WBC: 11.4 (7.7), SIRS: 3 (1); APACHE II: 19.2 (8); 60% had severe sepsis (61% Gram-negative; 39% Gram-positive). Sepsis source: 33% abdominal, 22% line, 19% urinary, 12% cutaneous; 8% pulmonary; 6% other. Findings: Day 0: PCT 4.62 (19), EAA 0.53 (0.24); Days to Clearance: PCT: 4.0 (4), EAA: 4.0 (4), and PCT/EAA: 4.0 (4). At the day of biomarker clearance patients also demonstrated clinical response. The median duration of antibiotics was 16 days [7 inpatient plus 9 outpatient-days]. Compared with both total and in-hospital antibiotic duration, time to clearance was significantly shorter: PCT (P < 0.0001), EAA (P < 0.0001), PCT/EAA (P < 0.0001). After multivariate adjustment for disease severity with APACHE II and organ failure, time-to-clearance for each or both biomarkers remained significantly shorter by 12 and 3 days compared with total and in-hospital antibiotic days, respectively. Additionally, a faster time to PCT/EAA clearance was associated with a 75% mortality reduction at 28 days (OR 0.25 (0.09–0.68); p = 0.007). CONCLUSION: The median time-to-clearance of procalcitonin and endotoxin was 4 days, and faster clearance was associated with significant mortality reduction. However, patients received additional 12 days of antibiotics. Our new findings support the use of shorter antibiotic courses for patients with bacteremic sepsis. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810774
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68107742019-10-28 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial Kalil, Andre C Florescu, Diana F Shafer, Laura R Van Schooneveld, Trevor C Open Forum Infect Dis Abstracts BACKGROUND: Patients hospitalized with sepsis are commonly treated with antibiotics for 10–21 days. Evidence is lacking to support this duration. We hypothesize that the sequential measurement of procalcitonin [PCT] (host biomarker) and endotoxin activity assay [EAA] (microorganism biomarker) could provide evidence to safely reduce antibiotic exposure. METHODS: Consented patients with bacteremic sepsis on antibiotics for <48 hours had PCT and EAA measured every other day until discharge or 14 days. Investigators and care providers were blinded to results. Median (interquartile), days to biomarker clearance (reduction from baseline PCT> 80% and EAA> 0.1), and univariate/multivariate regression done for all analyses. Clinical response was evaluated by blinded investigators. RESULTS: We enrolled 215 patients. Median age: 60 years old (18); Female 45%; Baseline: Temperature: 38.5°C (0.7); WBC: 11.4 (7.7), SIRS: 3 (1); APACHE II: 19.2 (8); 60% had severe sepsis (61% Gram-negative; 39% Gram-positive). Sepsis source: 33% abdominal, 22% line, 19% urinary, 12% cutaneous; 8% pulmonary; 6% other. Findings: Day 0: PCT 4.62 (19), EAA 0.53 (0.24); Days to Clearance: PCT: 4.0 (4), EAA: 4.0 (4), and PCT/EAA: 4.0 (4). At the day of biomarker clearance patients also demonstrated clinical response. The median duration of antibiotics was 16 days [7 inpatient plus 9 outpatient-days]. Compared with both total and in-hospital antibiotic duration, time to clearance was significantly shorter: PCT (P < 0.0001), EAA (P < 0.0001), PCT/EAA (P < 0.0001). After multivariate adjustment for disease severity with APACHE II and organ failure, time-to-clearance for each or both biomarkers remained significantly shorter by 12 and 3 days compared with total and in-hospital antibiotic days, respectively. Additionally, a faster time to PCT/EAA clearance was associated with a 75% mortality reduction at 28 days (OR 0.25 (0.09–0.68); p = 0.007). CONCLUSION: The median time-to-clearance of procalcitonin and endotoxin was 4 days, and faster clearance was associated with significant mortality reduction. However, patients received additional 12 days of antibiotics. Our new findings support the use of shorter antibiotic courses for patients with bacteremic sepsis. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810774/ http://dx.doi.org/10.1093/ofid/ofz360.1918 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kalil, Andre C
Florescu, Diana F
Shafer, Laura R
Van Schooneveld, Trevor C
2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title_full 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title_fullStr 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title_full_unstemmed 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title_short 2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
title_sort 2240. can antibiotic duration be reduced by the sequential use of procalcitonin and endotoxin in patients with sepsis? a prospective double-blind clinical trial
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810774/
http://dx.doi.org/10.1093/ofid/ofz360.1918
work_keys_str_mv AT kalilandrec 2240canantibioticdurationbereducedbythesequentialuseofprocalcitoninandendotoxininpatientswithsepsisaprospectivedoubleblindclinicaltrial
AT florescudianaf 2240canantibioticdurationbereducedbythesequentialuseofprocalcitoninandendotoxininpatientswithsepsisaprospectivedoubleblindclinicaltrial
AT shaferlaurar 2240canantibioticdurationbereducedbythesequentialuseofprocalcitoninandendotoxininpatientswithsepsisaprospectivedoubleblindclinicaltrial
AT vanschooneveldtrevorc 2240canantibioticdurationbereducedbythesequentialuseofprocalcitoninandendotoxininpatientswithsepsisaprospectivedoubleblindclinicaltrial